Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
for Leukemia, Lymphocytic, Chronic, B-Cell
84 locations incl. Birmingham
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Sex: All·Age: 18+
Code: NCT03331198·Phase 1, Phase 2·Recruiting